Research analysts at StockNews.com assumed coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) in a research note issued to investors on Monday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.
Titan Pharmaceuticals Trading Up 0.3 %
Titan Pharmaceuticals stock opened at $3.73 on Monday. Titan Pharmaceuticals has a 12 month low of $3.03 and a 12 month high of $14.80. The business’s 50 day simple moving average is $3.60 and its 200 day simple moving average is $4.10.
Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) last posted its quarterly earnings data on Friday, January 3rd. The specialty pharmaceutical company reported ($0.83) EPS for the quarter.
About Titan Pharmaceuticals
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
See Also
- Five stocks we like better than Titan Pharmaceuticals
- What is a Dividend King?
- Arqit Stock Soars as NVIDIA’s GTC Fuels Quantum Excitement
- Conference Calls and Individual Investors
- 3 Must-Own Stocks to Build Wealth This Decade
- Stock Analyst Ratings and Canadian Analyst Ratings
- Advanced Micro Devices Eyes AI Market Growth—Is AMD a Buy?
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
